Germany: Mainz Biomed shares spike higher from US IPO pricing

Shares in Mainz Biomed jumped impressively higher following the pricing of its US$10m IPO on Nasdaq. The molecular genetics diagnostics company specialising in the early detection of cancer, priced its share offering of 2 million common shares at US$5.00 per share on November 4, in the middle of the US$4 to US$6 marketing range. On…

You must be a HMI Subscriber to view this content.

Subscribe Now »